Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Overexpressed bcl-2 oncogene is linked to chemotherapy resistance, aggressive cancer, and poor patient survival.
• Bcl-2 is an anti-apoptotic protein crucial in cancer progression.
• Targeted gene-silencing strategies offer novel therapeutic avenues for cancer treatment.

Purpose of the Study:

• To review preclinical and clinical data of Oblimersen sodium, an antisense oligonucleotide targeting bcl-2 mRNA.
• To evaluate Oblimersen's efficacy and safety as a targeted anticancer therapy.
• To assess the potential of Oblimersen in combination with standard chemotherapy.

Main Methods:

• Oblimersen sodium is an 18-mer phosphorothioate antisense oligonucleotide targeting human bcl-2 mRNA.
• Preclinical studies and Phase I/II clinical trials assessed Oblimersen's biological activity and plasma levels.
• Phase III trials are evaluating Oblimersen combined with standard treatments in specific cancers.

Main Results:

• Oblimersen administration achieves biologically relevant plasma levels, leading to Bcl-2 protein downregulation.
• Combination therapy with Oblimersen and chemotherapy demonstrates promising response rates and good tolerability.
• Ongoing Phase III trials compare Oblimersen plus standard treatment versus standard treatment alone.

Conclusions:

• Oblimersen sodium represents a promising apoptosis-modulating strategy for cancer treatment.
• Targeted bcl-2 silencing via antisense oligonucleotides enhances anticancer treatment efficacy.
• Further clinical trials are essential to confirm Oblimersen's superiority in specific malignancies.